New drug candidate offers hope for Treatment-Resistant depression
Symptom relief
Completed
This phase 2 study tested a daily oral drug called MAP4343 in 126 adults whose depression did not improve with standard antidepressants. Participants took either MAP4343 or a placebo for 6 weeks. The main goal was to see if the drug reduced depression symptoms more than placebo, …
Phase: PHASE2 • Sponsor: Mapreg • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC